A significant trademark dispute concerning medicinal products came before the Delhi High Court, involving two major pharmaceutical companies and raising important questions regarding deceptive similarity, dishonest adoption, prior user rights, and pharmaceutical trademark protection. The Plaintiff, Sanofi, proprietor of the anti-thrombosis drug sold under the mark PLAVIX, instituted proceedings against Intas Pharmaceuticals Ltd. and its affiliates alleging trademark infringement, passing off, and seeking damages arising from the Defendants’ use of the mark CLAVIX.

The dispute centred around whether the Defendants’ use of CLAVIX for medicinal preparations containing Clopidogrel bisulphate infringed the Plaintiff’s statutory rights in PLAVIX. The case also gave the Court an opportunity to reiterate the stricter standards applicable in pharmaceutical trademark disputes, where even minor similarities between competing marks may endanger public health.

Background of the Dispute

Sanofi is a globally recognized pharmaceutical company engaged in the research, development, manufacture, and sale of medicinal products worldwide, including in India. One of its prominent products is the anti-thrombosis drug sold under the mark PLAVIX, prescribed for prevention of heart attacks and strokes. According to the Plaintiff, the mark PLAVIX was coined in 1995 and is an invented and inherently distinctive expression having no direct reference to either the active ingredient or the ailment treated by the drug.

The Plaintiff asserted that registrations for the word mark PLAVIX and its corresponding device mark had been obtained in Class 5 and continued to remain valid and subsisting. The drug was launched internationally in 1998 and introduced in India in January 2003. Owing to extensive worldwide sales, promotional activities, medical journal references, and internet visibility, the Plaintiff claimed that the mark had acquired substantial goodwill and reputation globally.

The dispute arose when the Plaintiff discovered in 2005 that the Defendants were manufacturing and marketing pharmaceutical products under the mark CLAVIX. It was subsequently found that the Defendants had also applied for registration of the impugned mark in Class 5 before the Trademarks Registry, which application was opposed by the Plaintiff.

Defendants’ Stand

The Defendants denied infringement and claimed independent adoption of the mark CLAVIX in 2001. According to them, the mark had been coined using components associated with the drug and its therapeutic indication. They contended that “CL” was derived from Clopidogrel, “AVI” from “Atherosclerotic Vascular Incidences,” while the letter “X” indicated reduction in recurrence of acute events.

The Defendants further argued that they had obtained the necessary manufacturing approvals in June and July 2001 and had continuously used the mark since then. Owing to prolonged use, extensive sales, and promotional expenditure, the Defendants claimed that CLAVIX had acquired goodwill and distinctiveness in the market.

Additionally, the Defendants invoked the defence of prior use under Section 34 of the Trademarks Act, 1999, contending that they had commenced use of CLAVIX in India prior to the Plaintiff’s launch of PLAVIX in India in 2003.

Findings of the Court

The Delhi High Court held that the Plaintiff had successfully established proprietorship over the marks PLAVIX and its device mark through documentary evidence and legal proceeding certificates.

Upon comparison of the competing marks, the Court concluded that CLAVIX was phonetically, visually, and structurally similar to PLAVIX. The only distinction between the two marks was the substitution of the letter “P” with the letter “C.” Since both marks were used in relation to identical pharmaceutical products containing the same active ingredient and intended for treatment of the same ailment, the possibility of confusion among consumers was considered extremely high.

The Court emphasized that medicinal products require a stricter standard while assessing deceptive similarity because confusion between pharmaceutical products may have serious health consequences.

Dishonest Adoption

A major aspect of the judgment was the Court’s finding of dishonest adoption. The explanation offered by the Defendants regarding derivation of the mark CLAVIX was found to be unconvincing. The Court noted that the expression “Atherosclerotic Vascular Incidences” had no recognized basis in medical literature and rejected the Defendants’ explanation regarding the significance of the letter “X.”

The Court also took note of the fact that the Defendants were already marketing the same drug under different marks such as PREVA and PRASUGEL. In these circumstances, there appeared to be no bona fide justification for adopting a mark so closely resembling PLAVIX.

The Court observed that a major pharmaceutical company would ordinarily conduct a basic trademark search before launching a medicinal product. The Court therefore found it implausible that the Defendants were unaware of the internationally marketed drug PLAVIX at the time of adoption of CLAVIX. Consequently, the Court concluded that the adoption of the impugned mark was dishonest and intended to ride upon the Plaintiff’s reputation.

Section 34 Defence Rejected

The Defendants attempted to invoke Section 34 of the Trademarks Act, which protects a prior user against claims of infringement. However, the Court clarified that protection under Section 34 is available only where the defendant’s use predates both the registration and use of the plaintiff’s mark, whichever is earlier.

Although the Defendants claimed use of CLAVIX since 2001, the Plaintiff’s registrations for PLAVIX dated back to 1995 and 1998. Accordingly, the Defendants failed to satisfy the statutory requirements necessary to invoke Section 34. The Court further held that a party guilty of dishonest adoption cannot seek equitable protection under the provision.

Passing Off Claim Fails

While the Plaintiff succeeded on infringement, the Court reached a different conclusion with respect to passing off. The Plaintiff attempted to establish trans-border reputation and goodwill in India through brochures, promotional materials, medical publications, and internet extracts. However, the Court found that the evidence did not sufficiently establish that PLAVIX had acquired substantial goodwill or reputation in India by 2001, when the Defendants launched CLAVIX.

Although certain doctors and hospitals in India had prescribed PLAVIX prior to its official launch in India in 2003, the Court held that such isolated instances only demonstrated sporadic awareness and not significant market reputation in India. Consequently, the Plaintiff failed to establish the necessary ingredients of passing off.

Delay and Damages

The Defendants also argued that the suit suffered from delay and laches. This contention was rejected by the Court, which observed that the Plaintiff became aware of the Defendants’ use of CLAVIX only in 2005 and instituted the suit within a reasonable period thereafter in 2008.

With respect to damages, the Court held that the Plaintiff failed to establish actual loss suffered by it or unlawful profits earned by the Defendants. Since damages cannot be awarded on speculative calculations, the claims for rendition of accounts and actual damages were rejected.

Nevertheless, considering the findings of trademark infringement and dishonest adoption, along with the fact that the Defendants had continued selling CLAVIX during the pendency of the suit owing to absence of an interim injunction, the Court awarded nominal damages of ₹20 lakhs to the Plaintiff.

Conclusion

In conclusion, the Delhi High Court decreed the suit in favour of the Plaintiff and permanently restrained the Defendants from manufacturing, selling, or dealing in pharmaceutical products under the mark CLAVIX or any deceptively similar mark amounting to infringement of the Plaintiff’s registered trademark PLAVIX.

The judgment serves as another important reaffirmation of the heightened threshold applied in pharmaceutical trademark disputes and underscores the judiciary’s continued emphasis on consumer safety, honest adoption, and protection of statutory trademark rights in the medicinal sector.